Investor FAQs

Investor FAQs

Show All

Where and when was Eidos Therapeutics incorporated?

Eidos Therapeutics was incorporated in 2013 by its academic co-founders. BridgeBio Pharma made its first investment into the company in 2016.

Who is Eidos Therapeutics’ transfer agent and how do I contact them?

Eidos Therapeutics’ transfer agent is American Stock Transfer & Trust Company, LLC. Please see below for the transfer agent contact information:

American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, New York 11219

Phone (US): 1.800.937.5449

Where is Eidos headquartered

101 Montgomery Street, Suite 2550, San Francisco, CA 94104

When did Eidos Therapeutics go public?

Eidos Therapeutics went public on June 19, 2018

On which exchange is Eidos Therapeutics listed and what is the ticker symbol?

Eidos Therapeutics' common stock is traded on the NASDAQ Global Select Market under the symbol “EIDX”.

How can I purchase shares?

A. Shares can be purchased through any registered broker. Eidos Therapeutics does not have a direct stock purchase plan.

Does Eidos Therapeutics pay dividends and have a dividend reinvestment program?

A. Currently, Eidos Therapeutics does not pay dividend or offer a dividend reinvestment program.

What is Eidos Therapeutics’ CUSIP number?

28249H 104

What is Eidos Therapeutics’ fiscal year-end?

Eidos Therapeutics’ fiscal year-end is December 31st

Who are Eidos Therapeutics’ independent auditors?


Where can I find recent Eidos Therapeutics’ releases?

A. You can view our recent press releases by visiting the “Press Releases” section of our website.

How can I sign up to receive Eidos Therapeutics’ press releases and other company information?

Please visit the “Investors & Media” section of our website and choose the "Email Alerts" button to be added to the Eidos Therapeutics distribution list.

How can I view documents Eidos Therapeutics has filed with the Securities & Exchange Commission (SEC), including Forms 10-K and 10-Q?

A. Quarterly and annual reports, as well as other SEC filings, can be accessed in the Financial & Filings section of our Investors & Media website page or directly from the SEC at

If I have questions regarding Eidos Therapeutics that have not been answered, whom should I contact?

Investor relations inquiries may be submitted to John Grimaldi at Burns McClellan at +1-212-213-0006 or